Cancer cells often display centrosome amplification, requiring the kinesin KIFC1/HSET for centrosome clustering to prevent multipolar spindles and cell death. In parallel siRNA screens of deubiquitinase enzymes, we identify OTUD6B as a positive regulator of KIFC1 expression that is required for centrosome clustering in triple-negative breast cancer (TNBC) cells. OTUD6B can localise to centrosomes and the mitotic spindle and interacts with KIFC1.
View Article and Find Full Text PDFSet-up errors are a problem for pre-clinical irradiators that lack imaging capabilities. The aim of this study was to investigate the impact of the potential set-up errors on the dose distribution for a mouse with a xenographic tumour irradiated with a standard Cs-137 cell irradiator equipped with an in-house lead collimator with 10 mm diameter apertures. The EGSnrc Monte-Carlo (MC) code was used to simulate the potential errors caused by displacements of the mouse in the irradiation setup.
View Article and Find Full Text PDFBackground: In Australia, a government insurance scheme (Medicare) pays set rebates for a range of distinct general practitioner (GP) services. GPs may 'bulk-bill' and accept the Medicare rebate fee directly, or 'privately-bill' by charging the patient a higher fee that is partially reimbursed by Medicare. The billing behaviour of Australian GP registrars (trainees) and their decision to bulk- or privately-bill patients is an evidence gap.
View Article and Find Full Text PDFBackground: The conventional lying down position for radiation therapy can be challenging for patients due to pain, swallowing or breathing issues. To provide an alternative upright treatment position for these patients, we have developed a portable rotating radiation therapy platform which integrates with conventional photon treatment machines. The device enables cone-beam computed tomography (CBCT) imaging of patients in an upright position, and the future delivery of therapeutic radiation.
View Article and Find Full Text PDFClinical trials to establish the efficacy of new agents in the adjuvant cancer setting typically take many years to complete. During that time, external factors can impact recruitment and reporting plans. An example is a new standard of care becoming available during the recruitment period.
View Article and Find Full Text PDF